|
May 15
|
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
|
|
May 14
|
Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug
|
|
May 13
|
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
|
|
May 2
|
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
|
|
Apr 11
|
Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?
|
|
Apr 4
|
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
|
|
Apr 1
|
Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript
|
|
Apr 1
|
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
|
|
Mar 29
|
Q4 2023 Kodiak Sciences Inc Earnings Call
|
|
Mar 28
|
Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results
|
|
Mar 28
|
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 26
|
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
|
|
Jan 30
|
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
|
|
Jan 4
|
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|